What is it about?
Acute Lymphoblastic Leukemia is one of the most common types of cancer in children. Although the treatment has improved still a lot of kids suffer relapses, identifying new biomarkers is essential to lower the percentage of relapses.
Featured Image
Why is it important?
About 10-15% of the kids wit Acute Lymphoblastic Leukemia will have relapses, identifying those at risk from the outset will improve the outcomes from the treatments
Read the Original
This page is a summary of: Myosin 1g as a high-risk biomarker in a pediatric patient with lineage switch from acute lymphoblastic leukemia to myeloid phenotype, Boletín Médico del Hospital Infantil de México, June 2023, Publicidad Permanyer, SLU,
DOI: 10.24875/bmhim.22000041.
You can read the full text:
Contributors
The following have contributed to this page
